application_number	drug_name_brand	drug_name_generic	url	indication	raw_biomarkers	involves_categorical_variants	categorical_variants
208716	Verzenio	abemaciclib	https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208716s010s011lbl.pdf	"Verzenio is a kinase inhibitor indicated in combination with endocrine therapy (tamoxifen or an aromatase inhibitor) for the adjuvant treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, node positive, early breast cancer at high risk of recurrence."	"HR+, HER2-negative"	FALSE	
208716	Verzenio	abemaciclib	https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208716s010s011lbl.pdf	"Verzenio is a kinase inhibitor indicated in combination with an aromatase inhibitor as initial endocrine-based therapy for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer."	"HR+, HER2-negative"	FALSE	
208716	Verzenio	abemaciclib	https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208716s010s011lbl.pdf	"Verzenio is a kinase inhibitor indicated in combination with fulvestrant for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer with disease progression following endocrine therapy."	"HR+, HER2-negative"	FALSE	
208716	Verzenio	abemaciclib	https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208716s010s011lbl.pdf	"Verzenio is a kinase inhibitor indicated as monotherapy for the treatment of adult patients with HR-positive, HER2-negative advanced or metastatic breast cancer with disease progression following endocrine therapy and prior chemotherapy in the metastatic setting."	"HR+, HER2-negative"	FALSE	
216793	Akeega	abiraterone acetate and niraparib	https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/216793s000lbl.pdf	"AKEEGA is a combination of niraparib, a poly (ADP-ribose) polymerase (PARP) inhibitor, and abiraterone acetate, a CYP17 inhibitor indicated with prednisone for the treatment of adult patients with deleterious or suspected deleterious BRCA-mutated (BRCAm) metastatic castration-resistant prostate cancer (mCRPC). Select patients for therapy based on an FDA-approved test for AKEEGA."	deleterious or suspected deleterious BRCA-mutated (BRCAm)	TRUE	(suspected) deleterious BRCA1 variants; (suspected) deleterious BRCA2 variants
216340	Krazati	adagrasib	https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/216340Orig1s000Corrected_lbl.pdf	"KRAZATI is an inhibitor of the RAS GTPase family indicated for the treatment of adult patients with KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC), as determined by an FDA approved test, who have received at least one prior systemic therapy. This indication is approved under accelerated approval based on objective response rate (ORR) and duration of response (DOR). Continued approval for this indication may be contingent upon verification and description of a clinical benefit in a confirmatory trial(s)."	KRAS G12C	FALSE	
125427	Kadcyla	ado-trastuzumab emtansine	https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/125427s111lbl.pdf	"KADCYLA is a HER2-targeted antibody and microtubule inhibitor conjugate indicated, as a single agent, for the treatment of patients with HER2-positive, metastatic breast cancer who previously received trastuzumab and a taxane, separately or in combination. Patients should have either: received prior therapy for metastatic disease; or developed disease recurrence during or within six months of completing adjuvant therapy. Select patients for therapy based on an FDA-approved companion diagnostic for KADCYLA."	HER2-positive	FALSE	
125427	Kadcyla	ado-trastuzumab emtansine	https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/125427s111lbl.pdf	"KADCYLA is a HER2-targeted antibody and microtubule inhibitor conjugate indicated, as a single agent, for the adjuvant treatment of patients with HER2-positive early breast cancer who have residual invasive disease after neoadjuvant taxane and trastuzumab-based treatment. Select patients for therapy based on an FDA-approved companion diagnostic for KADCYLA."	HER2-positive	FALSE	
201292	Gilotrif	afatinib	https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/201292s017lbl.pdf	GILOTRIF is a kinase inhibitor indicated for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have non-resistant epidermal growth factor receptor (EGFR) mutations as detected by an FDA-approved test (1.1) Limitations of Use: Safety and efficacy of GILOTRIF were not established in patients whose tumors have resistant EGFR mutations.	non-resistant EGFR mutations	TRUE	non-resistant EGFR variants
208434	Alecensa	alectinib	https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/208434s015lbl.pdf	ALECENSA is a kinase inhibitor indicated for the adjuvant treatment in adult patients following tumor resection of anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC) (tumors >= 4 cm or node positive) as detected by an FDA-approved test.	ALK-positive	TRUE	v::ALK
208434	Alecensa	alectinib	https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/208434s015lbl.pdf	ALECENSA is a kinase inhibitor indicated for the treatment of adult patients with ALK-positive metastatic NSCLC as detected by an FDA-approved test.	ALK-positive	TRUE	v::ALK
212526	Piqray	alpelisib	https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212526s009lbl.pdf	"PIQRAY is a kinase inhibitor indicated in combination with fulvestrant for the treatment of adults with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, PIK3CA-mutated, advanced or metastatic breast cancer as detected by an FDA-approved test following progression on or after an endocrine-based regimen."	"HR+, HER2-negative, PIK3CA-mutated"	TRUE	PIK3CA variants
761210	Rybrevant	amivantamab-vmjw	https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761210s004lbl.pdf	"RYBREVANT is a bispecific EGF receptor-directed and MET receptor-directed antibody indicated in combination with carboplatin and pemetrexed for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion mutations, as detected by an FDA-approved test."	EGFR exon 20 insertion mutations	TRUE	EGFR exon 20 insertion variants
761210	Rybrevant	amivantamab-vmjw	https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761210s004lbl.pdf	"RYBREVANT is a bispecific EGF receptor-directed and MET receptor-directed antibody indicated as a single agent for the treatment of adult patients with locally advanced or metastatic NSCLC with EGFR exon 20 insertion mutations, as detected by an FDA-approved test, whose disease has progressed on or after platinum-based chemotherapy."	EGFR exon 20 insertion mutations	TRUE	EGFR exon 20 insertion variants
21248	Trisenox	arsenic trioxide	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/021248s019lbl.pdf	TRISENOX is an arsenical indicated in combination with tretinoin for treatment of adults with newly-diagnosed low-risk acute promyelocytic leukemia (APL) whose APL is characterized by the presence of the t(15;17) translocation or PML/RAR-alpha gene expression.	t(15;17) translocation or PML/RAR-alpha gene expression	FALSE	
21248	Trisenox	arsenic trioxide	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/021248s019lbl.pdf	"TRISENOX is an arsenical indicated for induction of remission and consolidation in patients with APL who are refractory to, or have relapsed from, retinoid and anthracycline chemotherapy, and whose APL is characterized by the presence of the t(15;17) translocation or PML/RAR-alpha gene expression."	t(15;17) translocation or PML/RAR-alpha gene expression	FALSE	
215358	Scemblix	asciminib	https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/215358Orig1s008lbl.pdf	SCEMBLIX is a kinase inhibitor indicated for the treatment of adult patients with previously treated philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phase (CP).	philadelphia chromosome-positive	FALSE	
215358	Scemblix	asciminib	https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/215358Orig1s008lbl.pdf	SCEMBLIX is a kinase inhibitor indicated for the treatment of adult patients with Ph+ CML in CP with the T315I mutation.	philadelphia chromosome-positive with the T315I mutation	FALSE	
761034	Tecentriq	atezolizumab	https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761034s053lbl.pdf	"TECENTRIQ is a programmed death-ligand 1 (PD-L1) blocking antibody indicated as adjuvant treatment following resection and platinum-based chemotherapy for adult patients with Stage II to IIIA NSCLC whose tumors have PD-L1 expression on >= 1% of tumor cells, as determined by an FDA-approved test."	PD-L1 expression on >= 1% of tumor cells	FALSE	
761034	Tecentriq	atezolizumab	https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761034s053lbl.pdf	"TECENTRIQ is a programmed death-ligand 1 (PD-L1) blocking antibody indicated for the first-line treatment of adult patients with metastatic NSCLC whose tumors have high PD-L1 expression (PD-L1 stained >= 50% of tumor cells [TC >= 50%] or PD-L1 stained tumor-infiltrating immune cells [IC] covering >= 10% of the tumor area [IC >= 10%] ), as determined by an FDA-approved test, with no EGFR or ALK genomic tumor aberrations."	PD-L1 stained >= 50% of tumor cells [TC >= 50%] or PD-L1 stained tumor-infiltrating immune cells [IC] covering >= 10% of the tumor area [IC >= 10%])	FALSE	
761034	Tecentriq	atezolizumab	https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761034s053lbl.pdf	"TECENTRIQ is a programmed death-ligand 1 (PD-L1) blocking antibody indicated in combination with bevacizumab, paclitaxel, and carboplatin, for the first-line treatment of adult patients with metastatic non-squamous NSCLC with no EGFR or ALK genomic tumor aberrations."	no EGFR or ALK genomic tumor aberrations	FALSE	
761034	Tecentriq	atezolizumab	https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761034s053lbl.pdf	TECENTRIQ is a programmed death-ligand 1 (PD-L1) blocking antibody indicated in combination with paclitaxel protein-bound and carboplatin for the first-line treatment of adult patients with metastatic non-squamous NSCLC with no EGFR or ALK genomic tumor aberrations.	no EGFR or ALK genomic tumor aberrations	FALSE	
761034	Tecentriq	atezolizumab	https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761034s053lbl.pdf	TECENTRIQ is a programmed death-ligand 1 (PD-L1) blocking antibody indicated for the treatment of adult patients with metastatic NSCLC who have disease progression during or following platinum-containing chemotherapy. Patients with EGFR or ALK genomic tumor aberrations should have disease progression on FDA-approved therapy for NSCLC harboring these aberrations prior to receiving TECENTRIQ.	EGFR or ALK genomic tumor aberrations	TRUE	EGFR variants; ALK variants
761034	Tecentriq	atezolizumab	https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761034s053lbl.pdf	TECENTRIQ is a programmed death-ligand 1 (PD-L1) blocking antibody indicated in combination with cobimetinib and vemurafenib for the treatment of adult patients with BRAF V600 mutation-positive unresectable or metastatic melanoma.	BRAF V600	TRUE	BRAF V600
212608	Ayvakit	avapritinib	https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212608s013lbl.pdf	"AYVAKIT is a kinase inhibitor indicated for the treatment of adults with unresectable or metastatic GIST harboring a platelet-derived growth factor receptor alpha (PDGFRA) exon 18 mutation, including PDGFRA D842V mutations."	"PDGFRA exon 18 mutation, including PDGFRA D842V"	TRUE	PDGFRA exon 18 variants
210498	Mektovi	binimetinib	https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/210498s009lbl.pdf	"MEKTOVI is a kinase inhibitor indicated in combination with encorafenib, for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, as detected by an FDA-approved test."	BRAF V600E or V600K	FALSE	
210498	Mektovi	binimetinib	https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/210498s009lbl.pdf	"MEKTOVI is a kinase inhibitor indicated in combination with encorafenib, for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) with a BRAF V600E mutation, as detected by an FDA-approved test."	BRAF V600E	FALSE	
125557	Blincyto	blinatumomab	https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/125557Orig1s028Correctedlbl.pdf	BLINCYTO is a bispecific CD19-directed CD3 T-cell engager indicated for the treatment of adult and pediatric patients one month and older with CD19-positive B-cell precursor acute lymphoblastic leukemia (ALL) in first or second complete remission with minimal residual disease (MRD) greater than or equal to 0.1%.	CD19-positive	FALSE	
125557	Blincyto	blinatumomab	https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/125557Orig1s028Correctedlbl.pdf	BLINCYTO is a bispecific CD19-directed CD3 T-cell engager indicated for the treatment of adult and pediatric patients one month and older with relapsed or refractory CD19-positive B-cell precursor acute lymphoblastic leukemia (ALL).	CD19-positive	FALSE	
125557	Blincyto	blinatumomab	https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/125557Orig1s028Correctedlbl.pdf	BLINCYTO is a bispecific CD19-directed CD3 T-cell engager indicated for the treatment of adult and pediatric patients one month and older with CD19-positive Philadelphia chromosome-negative B-cell precursor acute lymphoblastic leukemia (ALL) in the consolidation phase of multiphase chemotherapy.	CD19-positive philadelphia chromosome-negative	FALSE	
203341	Bosulif	bosutinib	https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/203341s025lbl.pdf	"BOSULIF is a kinase inhibitor indicated for the treatment of adult and pediatric patients 1 year of age and older with chronic phase Ph+ chronic myelogenous leukemia (CML), newly-diagnosed or resistant or intolerant to prior therapy."	philadelphia chromosome-positive	FALSE	
203341	Bosulif	bosutinib	https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/203341s025lbl.pdf	"BOSULIF is a kinase inhibitor indicated for the treatment of adult patients with accelerated, or blast phase Ph+ CML with resistance or intolerance to prior therapy."	philadelphia chromosome-positive	FALSE	
125388	Adcetris	brentuximab vedotin	https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125388s107lbl.pdf	"ADCETRIS is a CD30-directed antibody and microtubule inhibitor conjugate indicated for treatment of adult patients with previously untreated systemic anaplastic large cell lymphoma (sALCL) or other CD30-expressing peripheral T-cell lymphomas (PTCL), including angioimmunoblastic T-cell lymphoma and PTCL not otherwise specified, in combination with cyclophosphamide, doxorubicin, and prednisone."	CD30-expressing	FALSE	
125388	Adcetris	brentuximab vedotin	https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125388s107lbl.pdf	ADCETRIS is a CD30-directed antibody and microtubule inhibitor conjugate indicated for treatment of adult patients with primary cutaneous anaplastic large cell lymphoma (pcALCL) or CD30-expressing mycosis fungoides (MF) who have received prior systemic therapy.	CD30-expressing	FALSE	
208772	Alunbrig	brigatinib	https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/208772s013lbl.pdf	ALUNBRIG is a kinase inhibitor indicated for the treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) as detected by an FDA-approved test.	ALK-positive	TRUE	v::ALK
20896	Xeloda	capecitabine	https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/020896s044s045s046s047s048s049s050s051lbl.pdf	XELODA (capecitabine) is a nucleoside metabolic inhibitor indicated for treatment of adults with HER2-overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma who have not received prior treatment for metastatic disease as a component of a combination regimen.	HER2-overexpressing	FALSE	
218197	Truqap	capivasertib	https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/218197s000lbl.pdf	"TRUQAP is a kinase inhibitor indicated, in combination with fulvestrant for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer with one or more PIK3CA/AKT1/PTEN-alterations as detected by an FDA-approved test following progression on at least one endocrine-based regimen in the metastatic setting or recurrence on or within 12 months of completing adjuvant therapy."	"HR+, HER2-negative with one or more PIK3CA/AKT1/PTEN-alterations"	TRUE	PIK3CA variants; AKT1 variants; PTEN variants
213591	Tabrecta	capmatinib	https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/213591s011lbl.pdf	TABRECTA is a kinase inhibitor indicated for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have a mutation that leads to mesenchymal-epithelial transition (MET) exon 14 skipping as detected by an FDA-approved test.	MET exon 14 skipping	TRUE	MET exon 14 skipping variants
761097	Libtayo	cemiplimab	https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761097s023lbl.pdf	"LIBTAYO is a programmed death receptor-1 (PD-1) blocking antibody indicated in combination with platinum-based chemotherapy for the first-line treatment of adult patients with non-small cell lung cancer (NSCLC) with no EGFR, ALK or ROS1 aberrations and is: (i) locally advanced where patients are not candidates for surgical resection or definitive chemoradiation or (ii) metastatic."	"no EGFR, ALK or ROS1 aberrations"	FALSE	
761097	Libtayo	cemiplimab	https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761097s023lbl.pdf	"LIBTAYO is a programmed death receptor-1 (PD-1) blocking antibody indicated as single agent for the first-line treatment of adult patients with NSCLC whose tumors have high PD-L1 expression [Tumor Proportion Score (TPS) >= 50%] as determined by an FDA-approved test, with no EGFR, ALK or ROS1 aberrations, and is: (i) locally advanced where patients are not candidates for surgical resection or definitive chemoradiation or (ii) metastatic."	"high PD-L1 expression [Tumor Proportion Score (TPS) >= 50%] with no EGFR, ALK or ROS1 aberrations"	FALSE	
211225	Zykadia	ceritinib	https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/211225s004lbl.pdf	ZYKADIA is a kinase inhibitor indicated for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are anaplastic lymphoma kinase (ALK)-positive as detected by an FDA-approved test.	ALK-positive	TRUE	v::ALK
125084	Erbitux	cetuximab	https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/125084s279lbl.pdf	"ERBITUX is an epidermal growth factor receptor (EGFR) antagonist indicated for treatment of K-Ras wild-type, EGFR-expressing, metastatic colorectal cancer as determined by an FDA-approved test in combination with FOLFIRI for first-line treatment."	"K-Ras wild type, EGFR-expressing"	FALSE	
125084	Erbitux	cetuximab	https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/125084s279lbl.pdf	"ERBITUX is an epidermal growth factor receptor (EGFR) antagonist indicated for treatment of K-Ras wild-type, EGFR-expressing, metastatic colorectal cancer as determined by an FDA-approved test in combination with irinotecan in patients who are refractory to irinotecan-based chemotherapy."	"K-Ras wild-type, EGFR-expressing"	FALSE	
125084	Erbitux	cetuximab	https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/125084s279lbl.pdf	"ERBITUX is an epidermal growth factor receptor (EGFR) antagonist indicated for treatment of K-Ras wild-type, EGFR-expressing, metastatic colorectal cancer as determined by an FDA-approved test as a single-agent in patients who have failed oxaliplatin- and irinotecan-based chemotherapy or who are intolerant to irinotecan."	"K-Ras wild type, EGFR-expressing"	FALSE	
125084	Erbitux	cetuximab	https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/125084s279lbl.pdf	"ERBITUX is an epidermal growth factor receptor (EGFR) antagonist indicated for treatment of in combination with encorafenib, for the treatment of adult patients with metastatic colorectal cancer (CRC) with a BRAF V600E mutation, as detected by an FDA-approved test, after prior therapy."	BRAF V600E	FALSE	
206192	Cotellic	cobimetinib	https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/206192s006lbl.pdf	"COTELLIC is a kinase inhibitor indicated for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, in combination with vemurafenib."	BRAF V600E or V600K	FALSE	
202570	Xalkori	crizotinib	https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/202570s036lbl.pdf	XALKORI is a kinase inhibitor indicated for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are anaplastic lymphoma kinase (ALK) or ROS1-positive as detected by an FDA-approved test.	ALK or ROS1-positive	TRUE	v::ALK
202570	Xalkori	crizotinib	https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/202570s036lbl.pdf	"XALKORI is a kinase inhibitor indicated for the treatment of pediatric patients 1 year of age and older and young adults with relapsed or refractory, systemic anaplastic large cell lymphoma (ALCL) that is ALK-positive. Limitations of Use: The safety and efficacy of XALKORI have not been established in older adults with relapsed or refractory, systemic ALK-positive ALCL."	ALK-positive	TRUE	v::ALK; v::ROS1
202570	Xalkori	crizotinib	https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/202570s036lbl.pdf	"XALKORI is a kinase inhibitor indicated for the treatment of adult and pediatric patients 1 year of age and older with unresectable, recurrent, or refractory inflammatory myofibroblastic tumor (IMT) that is ALK-positive."	ALK-positive	TRUE	v::ALK; v::ROS1
202806	Tafinlar	dabrafenib	https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/202806s030lbl.pdf	TAFINLAR is a kinase inhibitor indicated as a single agent for the treatment of patients with unresectable or metastatic melanoma with BRAF V600E mutation as detected by an FDA-approved test.	BRAF V600E	FALSE	
202806	Tafinlar	dabrafenib	https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/202806s030lbl.pdf	"TAFINLAR is indicated, in combination with trametinib, for the treatment of patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutations as detected by an FDA-approved test."	BRAF V600E or BRAF V600K	FALSE	
202806	Tafinlar	dabrafenib	https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/202806s030lbl.pdf	"TAFINLAR is indicated, in combination with trametinib, for the adjuvant treatment of patients with melanoma with BRAF V600E or V600K mutations, as detected by an FDA-approved test, and involvement of lymph node(s), following complete resection."	BRAF V600E or BRAF V600K	FALSE	
202806	Tafinlar	dabrafenib	https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/202806s030lbl.pdf	"TAFINLAR is indicated, in combination with trametinib, for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) with BRAF V600E mutation as detected by an FDA-approved test."	BRAF V600E	FALSE	
202806	Tafinlar	dabrafenib	https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/202806s030lbl.pdf	"TAFINLAR is indicated, in combination with trametinib, for the treatment of patients with locally advanced or metastatic anaplastic thyroid cancer (ATC) with BRAF V600E mutation and with no satisfactory locoregional treatment options."	BRAF V600E	FALSE	
202806	Tafinlar	dabrafenib	https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/202806s030lbl.pdf	"TAFINLAR is indicated, in combination with trametinib, for the treatment of adult and pediatric patients 1 year of age and older with unresectable or metastatic solid tumors with BRAF V600E mutation who have progressed following prior treatment and have no satisfactory alternative treatment options. This indication is approved under accelerated approval based on overall response rate (ORR) and duration of response (DoR). Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s)."	BRAF V600E	FALSE	
202806	Tafinlar	dabrafenib	https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/202806s030lbl.pdf	"TAFINLAR is indicated, in combination with trametinib, for the treatment of pediatric patients 1 year of age and older with low-grade glioma (LGG) with a BRAF V600E mutation who require systemic therapy."	BRAF V600E	FALSE	
211288	Vizimpro	dacomitinib	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/211288s003lbl.pdf	VIZIMPRO is a kinase inhibitor indicated for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletion or exon 21 L858R substitution mutations as detected by an FDA-approved test.	EGFR exon 19 deletion or exon 21 L858R substitution mutations	TRUE	EGFR exon 19 deletion variants
21986	Sprycel	dasatinib	https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/021986s027lbl.pdf	SPRYCEL is a kinase inhibitor indicated for the treatment of newly diagnosed adults with Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) in chronic phase.	philadelphia chromosome-positive (Ph+)	FALSE	
21986	Sprycel	dasatinib	https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/021986s027lbl.pdf	"SPRYCEL is a kinase inhibitor indicated for the treatment of adults with chronic, accelerated, or myeloid or lymphoid blast phase Ph+ CML with resistance or intolerance to prior therapy including imatinib."	philadelphia chromosome-positive	FALSE	
21986	Sprycel	dasatinib	https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/021986s027lbl.pdf	SPRYCEL is a kinase inhibitor indicated for the treatment of adults with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) with resistance or intolerance to prior therapy.	philadelphia chromosome-positive	FALSE	
21986	Sprycel	dasatinib	https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/021986s027lbl.pdf	SPRYCEL is a kinase inhibitor indicated for the treatment of pediatric patients 1 year of age and older with Ph+ CML in chronic phase.	philadelphia chromosome-positive (Ph+)	FALSE	
21986	Sprycel	dasatinib	https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/021986s027lbl.pdf	SPRYCEL is a kinase inhibitor indicated for the treatment of pediatric patients 1 year of age and older with newly diagnosed Ph+ ALL in combination with chemotherapy.	philadelphia chromosome-positive (Ph+)	FALSE	
761174	Jemperli	dostarlimab	https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761174s010lbl.pdf	"JEMPERLI is a programmed death receptor-1 (PD-1)-blocking antibody indicated in combination with carboplatin and paclitaxel, followed by JEMPERLI as a single agent for the treatment of adult patients with primary advanced or recurrent endometrial cancer that is mismatch repair deficient (dMMR), as determined by an FDA-approved test, or microstallite instability-high (MSI-H)."	mismatch repair deficient (dMMR) or microsatellite instability-high (MSI-H)	FALSE	
761174	Jemperli	dostarlimab	https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761174s010lbl.pdf	"JEMPERLI is a programmed death receptor-1 (PD-1)-blocking antibody indicated as a single agent for the treatment of adult patients with dMMR recurrent or advanced endometrial cancer, as determined by an FDA-approved test, that has progressed on or following prior treatment with a platinum-containing regimen in any setting and are not candidates for curative surgery or radiation."	dMMR	FALSE	
761174	Jemperli	dostarlimab	https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761174s010lbl.pdf	"JEMPERLI is a programmed death receptor-1 (PD-1)-blocking antibody indicated as a single agent for the treatment of adult patients with dMMR recurrent or advanced solid tumors, as determined by an FDA-approved test, that have progressed on or following prior treatment and who have no satisfactory alternative treatment options. This indication is approved under accelerated approval based on tumor response rate and durability of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s)."	dMMR	FALSE	
761069	Imfinzi	durvalumab	https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761069s043lbledt.pdf	"IMFINZI is a programmed death-ligand 1 (PD-L1) blocking antibody indicated in combination with tremelimumab-actl and platinum-based chemotherapy, for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) with no sensitizing epidermal growth factor receptor (EGFR) mutations or anaplastic lymphoma kinase (ALK) genomic aberrations."	no sensitizing EGFR mutations or ALK genomic aberrations	FALSE	
761069	Imfinzi	durvalumab	https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761069s043lbledt.pdf	"IMFINZI is a programmed death-ligand 1 (PD-L1) blocking antibody indicated in combination with carboplatin and paclitaxel followed by IMFINZI as a single agent, for the treatment of adult patients with primary advanced or recurrent endometrial cancer that is mismatch repair deficient (dMMR)."	mismatch repair deficient (dMMR)	FALSE	
217639	Orserdu	elacestrant	https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/217639Orig1s001lbl.pdf	"ORSERDU is an estrogen receptor antagonist indicated for treatment of postmenopausal women or adult men, with ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer with disease progression following at least one line of endocrine therapy."	"ER-positive, HER2-negative, ESR1-mutated"	FALSE	
209606	Idhifa	enasidenib	https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/209606s006lbl.pdf	IDHIFA is an isocitrate dehydrogenase-2 inhibitor indicated for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with an isocitrate dehydrogenase-2 (IDH2) mutation as detected by an FDA-approved test.	IDH2 mutation	TRUE	IDH2 variants
210496	Braftovi	encorafenib	https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/210496s017lbl.pdf	"BRAFTOVI is a kinase inhibitor indicated in combination with binimetinib, for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, as detected by an FDA-approved test. BRAFTOVI is not indicated for treatment of patients with wild-type BRAF melanoma, wild-type BRAF CRC, or wild-type BRAF NSCLC."	BRAF V600E or BRAF V600K	FALSE	
210496	Braftovi	encorafenib	https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/210496s017lbl.pdf	"BRAFTOVI is a kinase inhibitor indicated in combination with cetuximab, for the treatment of adult patients with metastatic colorectal cancer (CRC) with a BRAF V600E mutation, as detected by an FDA-approved test, after prior therapy. BRAFTOVI is not indicated for treatment of patients with wild-type BRAF melanoma, wild-type BRAF CRC, or wild-type BRAF NSCLC."	BRAF V600E	FALSE	
210496	Braftovi	encorafenib	https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/210496s017lbl.pdf	"BRAFTOVI is a kinase inhibitor indicated in combination with binimetinib, for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) with a BRAF V600E mutation, as detected by an FDA-approved test. BRAFTOVI is not indicated for treatment of patients with wild-type BRAF melanoma, wild-type BRAF CRC, or wild-type BRAF NSCLC."	BRAF V600E	FALSE	
212725	Rozlytrek	entrectinib	https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212725s011lbl.pdf	ROZLYTREK is a kinase inhibitor indicated for the treatment of adult patients with ROS1-positive metastatic non-small cell lung cancer (NSCLC) as detected by an FDA-approved test.	ROS1-positive	TRUE	v::ROS1
212725	Rozlytrek	entrectinib	https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212725s011lbl.pdf	"ROZLYTREK is a kinase inhibitor indicated for the treatment of adult and pediatric patients older than 1 month of age with solid tumors that: (i) have a neurotrophic tyrosine receptor kinase (NTRK) gene fusion, as detected by an FDA-approved test without a known acquired resistance mutation, (ii) are metastatic or where surgical resection is likely to result in severe morbidity, and (iii) have progressed following treatment or have no satisfactory alternative therapy. This indication is approved under accelerated approval based on tumor response rate and durability of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trials."	NTRK gene fusion	TRUE	v::NTRK1; v::NTRK2; v::NTRK3
212018	Balversa	erdafitinib	https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212018s007s008s009lbl.pdf	BALVERSA is a kinase inhibitor indicated for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma (mUC) with susceptible FGFR3 genetic alterations whose disease has progressed on or after at least one line of prior systemic therapy. Select patients for therapy based on an FDA-approved companion diagnostic for BALVERSA. BALVERSA is not recommended for the treatment of patients who are eligible for and have not received prior PD-1 or PD-L1 inhibitor therapy.	susceptible FGFR3 genetic alterations	TRUE	susceptible FGFR3 variants
21743	Tarceva	erlotinib	https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/021743s025lbl.pdf	"TARCEVA is a kinase inhibitor indicated for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations as detected by an FDA-approved test receiving first-line, maintenance, or second or greater line treatment after progression following at least one prior chemotherapy regimen. Safety and efficacy of TARCEVA have not been established in patients with NSCLC whose tumors have other EGFR mutations. TARCEVA is not recommended for use in combination with platinum-based chemotherapy."	EGFR exon 19 deletions or exon 21 L858R	TRUE	EGFR exon 19 deletion variants
22334	Afinitor	everolimus	"https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/203985s023,022334s051lbl.pdf"	"AFINITOR is a kinase inhibitor indicated for the treatment of postmenopausal women with advanced hormone receptor-positive, HER2 negative breast cancer in combination with exemestane after failure of treatment with letrozole or anastrozole."	"HR+, HER2-negative"	FALSE	
21344	Faslodex	fulvestrant	https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/021344s044lbl.pdf	"FASLODEX is an estrogen receptor antagonist indicated for the treatment of hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer in postmenopausal women not previously treated with endocrine therapy."	"HR+, HER2-negative"	FALSE	
21344	Faslodex	fulvestrant	https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/021344s044lbl.pdf	FASLODEX is an estrogen receptor antagonist indicated for the treatment of HR-positive advanced breast cancer in postmenopausal women with disease progression following endocrine therapy.	HR+	FALSE	
21344	Faslodex	fulvestrant	https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/021344s044lbl.pdf	"FASLODEX is an estrogen receptor antagonist indicated for the treatment of HR-positive, HER2-negative advanced or metastatic breast cancer in postmenopausal women in combination with ribociclib, as initial endocrine based therapy or following disease progression on endocrine therapy."	"HR+, HER2-negative"	FALSE	
21344	Faslodex	fulvestrant	https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/021344s044lbl.pdf	"FASLODEX is an estrogen receptor antagonist indicated for the treatment of HR-positive, HER2-negative advanced or metastatic breast cancer in combination with palbociclib or abemaciclib in women with disease progression after endocrine therapy."	"HR+, HER2-negative"	FALSE	
214801	Lytgobi	futibatinib	https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/214801s002lbl.pdf	"LYTGOBI is a kinase inhibitor indicated for the treatment of adult patients with previously treated, unresectable, locally advanced or metastatic intrahepatic cholangiocarcinoma harboring fibroblast growth factor receptor 2 (FGFR2) gene fusions or other rearrangements. This indication is approved under accelerated approval based on overall response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s)."	FGFR2 gene fusions or other rearrangements	TRUE	FGFR2::v; FGFR2 rearrangements
206995	Iressa	gefitinib	https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/206995s004lbl.pdf	IRESSA is a tyrosine kinase inhibitor indicated for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations as detected by an FDA-approved test. Limitation of Use: Safety and efficacy of IRESSA have not been established in patients whose tumors have EGFR mutations other than exon 19 deletions or exon 21 (L858R) substitution mutations.	EGFR exon 19 deletions or exon 21 (L858R) substitution mutations	TRUE	EGFR exon 19 deletion variants
761060	Mylotarg	gemtuzumab ozogamicin	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761060s004lbl.pdf	MYLOTARG is a CD33-directed antibody and cytotoxic drug conjugate indicated for treatment of newly-diagnosed CD33-positive acute myeloid leukemia (AML) in adults and pediatric patients 1 month and older.	CD33-positive	FALSE	
761060	Mylotarg	gemtuzumab ozogamicin	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761060s004lbl.pdf	MYLOTARG is a CD33-directed antibody and cytotoxic drug conjugate indicated for treatment of relapsed or refractory CD33-positive AML in adults and pediatric patients 2 years and older.	CD33-positive	FALSE	
211349	Xospata	gilteritinib	https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/211349s003lbl.pdf	XOSPATA is a kinase inhibitor indicated for the treatment of adult patients who have relapsed or refractory acute myeloid leukemia (AML) with a FLT3 mutation as detected by an FDA-approved test.	FLT3 mutation	TRUE	FLT3 variants
21588	Gleevec	imatinib	https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/021588s062lbl.pdf	Gleevec is a kinase inhibitor indicated for the treatment of newly diagnosed adult and pediatric patients with Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in chronic phase.	philadelphia chromosome-positive	FALSE	
21588	Gleevec	imatinib	https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/021588s062lbl.pdf	"Gleevec is a kinase inhibitor indicated for the treatment of patients with Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in blast crisis (BC), accelerated phase (AP), or in chronic phase (CP) after failure of interferon-alpha therapy."	philadelphia chromosome-positive	FALSE	
21588	Gleevec	imatinib	https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/021588s062lbl.pdf	Gleevec is a kinase inhibitor indicated for the treatment of adult patients with relapsed or refractory Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL).	philadelphia chromosome-positive	FALSE	
21588	Gleevec	imatinib	https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/021588s062lbl.pdf	Gleevec is a kinase inhibitor indicated for the treatment of pediatric patients with newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL) in combination with chemotherapy.	philadelphia chromosome-positive	FALSE	
21588	Gleevec	imatinib	https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/021588s062lbl.pdf	Gleevec is a kinase inhibitor indicated for the treatment of adult patients with myelodysplastic/myeloproliferative diseases (MDS/MPD) associated with platelet-derived growth factor receptor (PDGFR) gene re-arrangements.	platelet-derived growth factor receptor (PDGFR) gene re-arrangements	TRUE	PDGFRA rearrangement; PDGFRB rearrangement
21588	Gleevec	imatinib	https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/021588s062lbl.pdf	Gleevec is a kinase inhibitor indicated for the treatment of adult patients with aggressive systemic mastocytosis (ASM) without the D816V c-Kit mutation or with c-Kit mutational status unknown.	without the D816V c-Kit mutation or with the c-Kit mutational status unknown	FALSE	
21588	Gleevec	imatinib	https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/021588s062lbl.pdf	Gleevec is a kinase inhibitor indicated for the treatment of adult patients with hypereosinophilic syndrome (HES) and/or chronic eosinophilic leukemia (CEL) who have the FIP1L1-PDGFRa fusion kinase (mutational analysis or fluorescence in situ hybridization [FISH] demonstration of CHIC2 allele deletion) and for patients with HES and/or CEL who are FIP1L1-PDGFRa fusion kinase negative or unknown.	FIP1L1-PDGFRa fusion kinase and for patients ... who are FIP1L1-PDGFRa fusion kinase negative or unknown	FALSE	
21588	Gleevec	imatinib	https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/021588s062lbl.pdf	Gleevec is a kinase inhibitor indicated for the treatment of patients with Kit (CD117) positive unresectable and/or metastatic malignant gastrointestinal stromal tumors (GIST).	Kit (CD117) positive	FALSE	
21588	Gleevec	imatinib	https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/021588s062lbl.pdf	Gleevec is a kinase inhibitor indicated for the adjuvant treatment of adult patients following resection of Kit (CD117) positive GIST.	Kit (CD117) positive	FALSE	
214622	Truseltiq	infigratinib	https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/214622s000lbl.pdf	"TRUSELTIQ is a kinase inhibitor indicated for the treatment of adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (FGFR2) fusion or other rearrangement as detected by an FDA-approved test. This indication is approved under accelerated approval based on overall response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trial(s)."	FGFR2 fusion or other rearrangement	TRUE	FGFR2::v; FGFR2 rearrangements
761040	Besponsa	inotuzumab ozogamicin	https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761040s003lbl.pdf	BESPONSA is a CD22-directed antibody and cytotoxic drug conjugate indicated for the treatment of relapsed or refractory CD22-positive B-cell precursor acute lymphoblastic leukemia (ALL) in adult and pediatric patients 1 year and older.	CD22-positive	FALSE	
125377	Yervoy	ipilimumab	https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/125377s133lbl.pdf	YERVOY is a human cytotoxic T-lymphocyte antigen 4 (CTLA-4)-blocking antibody indicated for treatment of adult and pediatric patients 12 years and older with unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) colorectal cancer in combination with nivolumab.	microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR)	FALSE	
125377	Yervoy	ipilimumab	https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/125377s133lbl.pdf	"YERVOY is a human cytotoxic T-lymphocyte antigen 4 (CTLA-4)-blocking antibody indicated for treatment of adult patients with metastatic non-small cell lung cancer expressing PD-L1 (>=1%) as determined by an FDA-approved test, with no EGFR or ALK genomic tumor aberrations, as first-line treatment in combination with nivolumab."	PD-L1 >= 1% and no EGFR or ALK genomic tumor aberrations	FALSE	
125377	Yervoy	ipilimumab	https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/125377s133lbl.pdf	"YERVOY is a human cytotoxic T-lymphocyte antigen 4 (CTLA-4)-blocking antibody indicated for treatment of adult patients with metastatic or recurrent non-small cell lung cancer with no EGFR or ALK genomic tumor aberrations as first-line treatment, in combination with nivolumab and 2 cycles of platinum-doublet chemotherapy."	no EGFR or ALK genomic tumor aberrations	FALSE	
211192	Tibsovo	ivosidenib	https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211192s011lbl.pdf	"TIBSOVO is an isocitrate dehydrogenase-1 (IDH1) inhibitor indicated for patients with a susceptible IDH1 mutation as detected by an FDA-approved test with in combination with azacitidine or as monotherapy for the treatment of newly diagnosed AML in adults 75 years or older, or who have comorbidities that preclude use of intensive induction chemotherapy."	susceptible IDH1 mutation	TRUE	susceptible IDH1 variants
211192	Tibsovo	ivosidenib	https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211192s011lbl.pdf	TIBSOVO is an isocitrate dehydrogenase-1 (IDH1) inhibitor indicated for patients with a susceptible IDH1 mutation as detected by an FDA-approved test with for the treatment of adult patients with relapsed or refractory AML.	susceptible IDH1 mutation	TRUE	susceptible IDH1 variants
211192	Tibsovo	ivosidenib	https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211192s011lbl.pdf	TIBSOVO is an isocitrate dehydrogenase-1 (IDH1) inhibitor indicated for patients with a susceptible IDH1 mutation as detected by an FDA-approved test with for the treatment of adult patients with relapsed or refractory myelodysplastic syndromes.	susceptible IDH1 mutation	TRUE	susceptible IDH1 variants
211192	Tibsovo	ivosidenib	https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211192s011lbl.pdf	TIBSOVO is an isocitrate dehydrogenase-1 (IDH1) inhibitor indicated for patients with a susceptible IDH1 mutation as detected by an FDA-approved test with for the treatment of adult patients with locally advanced or metastatic cholangiocarcinoma who have been previously treated.	susceptible IDH1 mutation	TRUE	susceptible IDH1 variants
22059	Tykerb	lapatinib	https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/022059s031lbl.pdf	"TYKERB is a kinase inhibitor indicated in combination with capecitabine for the treatment of patients with advanced or metastatic breast cancer whose tumors overexpress human epidermal growth factor receptor 2 (HER2) and who have received prior therapy, including an anthracycline, a taxane, and trastuzumab. Limitations of Use: Patients should have disease progression on trastuzumab prior to initiation of treatment with TYKERB in combination with capecitabine. TYKERB in combination with an aromatase inhibitor has not been compared to a trastuzumab-containing chemotherapy regimen for the treatment of metastatic breast cancer."	HER2 overexpression	FALSE	
22059	Tykerb	lapatinib	https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/022059s031lbl.pdf	TYKERB is a kinase inhibitor indicated in combination with letrozole for the treatment of postmenopausal women with hormone receptor-positive metastatic breast cancer that overexpresses the HER2 receptor for whom hormonal therapy is indicated. TYKERB in combination with an aromatase inhibitor has not been compared to a trastuzumab-containing chemotherapy regimen for the treatment of metastatic breast cancer.	"HR+, HER2 overexpression"	FALSE	
210861	Vitrakvi	larotrectinib	https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/210861s012lbl.pdf	"VITRAKVI is a kinase inhibitor indicated for the treatment of adult and pediatric patients with solid tumors that: have a neurotrophic receptor tyrosine kinase (NTRK) gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or that have progressed following treatment. Select patients for therapy based on an FDA-approved test."	NTRK gene fusion	TRUE	susceptible IDH1 variants
21880	Revlimid	lenalidomide	https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/021880s067lbl.pdf	REVLIMID is a thalidomide analogue indicated for the treatment of adult patients with transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes (MDS) associated with a deletion 5q abnormality with or without additional cytogenetic abnormalities.	5q deletion	FALSE	
210868	Lorbrena	lorlatinib	https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/210868s004lbl.pdf	LORBRENA is a kinase inhibitor indicated for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are anaplastic lymphoma kinase (ALK)-positive as detected by an FDA-approved test.	ALK-positive	TRUE	v::NTRK1; v::NTRK2; v::NTRK3
761150	Margenza	margetuximab-cmkb	https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/761150s005lbl.pdf	"MARGENZA is a HER2/neu receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2- positive breast cancer who have received two or more prior anti-HER2 regimens, at least one of which was for metastatic disease."	HER2-positive	FALSE	
207997	Rydapt	midostaurin	https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/207997s010lbl.pdf	"RYDAPT is a kinase inhibitor indicated for the treatment of adult patients with newly diagnosed acute myeloid leukemia (AML) that is FLT3 mutation- positive as detected by an FDA-approved test, in combination with standard cytarabine and daunorubicin induction and cytarabine consolidation. RYDAPT is not indicated as a single-agent induction therapy for the treatment of patients with AML."	FLT3 mutation-positive	TRUE	FLT3 variants
215310	Exkivity	mobocertinib	https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/215310s003lbl.pdf	"EXKIVITY is a kinase inhibitor indicated for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion mutations, as detected by an FDA-approved test, whose disease has progressed on or after platinum-based chemotherapy. This indication is approved under accelerated approval based on overall response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trial(s)."	EGFR exon 20 insertion mutations	TRUE	EGFR exon 20 insertion variants
208051	Nerlynx	neratinib	https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/208051s009lbl.pdf	"NERLYNX is a kinase inhibitor indicated as a single agent, for the extended adjuvant treatment of adult patients with early-stage HER2-positive breast cancer, to follow adjuvant trastuzumab based therapy."	HER2-positive	FALSE	
208051	Nerlynx	neratinib	https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/208051s009lbl.pdf	"NERLYNX is a kinase inhibitor indicated in combination with capecitabine, for the treatment of adult patients with advanced or metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 based regimens in the metastatic setting."	HER2-positive	FALSE	
22068	Tasigna	nilotinib	https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/022068s041lbl.pdf	Tasigna is a kinase inhibitor indicated for the treatment of adult and pediatric patients greater than or equal to 1 year of age with newly diagnosed Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in chronic phase.	philadelphia chromosome-positive	FALSE	
22068	Tasigna	nilotinib	https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/022068s041lbl.pdf	Tasigna is a kinase inhibitor indicated for the treatment of adult patients with chronic phase (CP) and accelerated phase (AP) Ph+ CML resistant to or intolerant to prior therapy that included imatinib.	philadelphia chromosome-positive	FALSE	
22068	Tasigna	nilotinib	https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/022068s041lbl.pdf	Tasigna is a kinase inhibitor indicated for the treatment of pediatric patients greater than or equal to 1 year of age with Ph+ CML-CP and CML-AP resistant or intolerant to prior tyrosine-kinase inhibitor (TKI) therapy.	philadelphia chromosome-positive	FALSE	
214876	Zejula	niraparib	https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/214876s000lbl.pdf	"ZEJULA is a poly (ADP-ribose) polymerase (PARP) inhibitor indicated for the maintenance treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in complete or partial response to platinum-based chemotherapy. Select patients for therapy based on an FDA-approved companion diagnostic for ZEJULA."	deleterious or suspected deleterious germline BRCA-mutated	TRUE	(suspected) deleterious gBRCA1 variants; (suspected) deleterious gBRCA2 variants
125554	Opdivo	nivolumab	https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/125554s129lbl.pdf	"OPDIVO is a programmed death receptor-1 (PD-1) blocking antibody indicated for the treatment of adult patients with resectable (tumors >=4 cm or node positive) non-small cell lung cancer and no known EGFR mutations or ALK rearrangements, for neoadjuvant treatment, in combination with platinum-doublet chemotherapy, followed by single-agent OPDIVO as adjuvant treatment after surgery."	no known EGFR mutations or ALK rearrangement	FALSE	
208558	Lynparza	olaparib	https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf	"Lynparza is a poly (ADP-ribose) polymerase (PARP) inhibitor indicated for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy. Select patients for therapy based on an FDA-approved companion diagnostic for Lynparza."	deleterious or suspected deleterious germline or somatic BRCA-mutated	TRUE	(suspected) deleterious gBRCA1 variants; (suspected) deleterious gBRCA2 variants
208558	Lynparza	olaparib	https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf	"Lynparza is a poly (ADP-ribose) polymerase (PARP) inhibitor indicated in combination with bevacizumab for the maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy and whose cancer is associated with homologous recombination deficiency (HRD)-positive status defined by either a deleterious or suspected deleterious BRCA mutation, and/or genomic instability. Select patients for therapy based on an FDA-approved companion diagnostic for Lynparza."	HRD-positive defined by either a deleterious or suspected deleterious BRCA mutation and/or genomic instability	TRUE	(suspected) deleterious gBRCA1 variants; (suspected) deleterious gBRCA2 variants
208558	Lynparza	olaparib	https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf	"Lynparza is a poly (ADP-ribose) polymerase (PARP) inhibitor indicated for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer, who are in complete or partial response to platinum-based chemotherapy. Select patients for therapy based on an FDA-approved companion diagnostic for Lynparza."	deleterious or suspected deleterious germline or somatic BRCA-mutated	TRUE	(suspected) deleterious gBRCA1 variants; (suspected) deleterious gBRCA2 variants
208558	Lynparza	olaparib	https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf	Lynparza is a poly (ADP-ribose) polymerase (PARP) inhibitor indicated for the adjuvant treatment of adult patients with deleterious or suspected deleterious gBRCAm human epidermal growth factor receptor 2 (HER2)-negative high risk early breast cancer who have been treated with neoadjuvant or adjuvant chemotherapy. Select patients for therapy based on an FDA-approved companion diagnostic for Lynparza.	"deleterious or suspected deleterious gBRCAm, HER2-negative"	TRUE	(suspected) deleterious gBRCA1 variants; (suspected) deleterious gBRCA2 variants
208558	Lynparza	olaparib	https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf	"Lynparza is a poly (ADP-ribose) polymerase (PARP) inhibitor indicated for the treatment of adult patients with deleterious or suspected deleterious gBRCAm, HER2-negative metastatic breast cancer who have been treated with chemotherapy in the neoadjuvant, adjuvant or metastatic setting. Patients with hormone receptor (HR)-positive breast cancer should have been treated with a prior endocrine therapy or be considered inappropriate for endocrine therapy. Select patients for therapy based on an FDA-approved companion diagnostic for Lynparza."	"deleterious or suspected deleterious gBRCAm, HER2-negative"	TRUE	(suspected) deleterious gBRCA1 variants; (suspected) deleterious gBRCA2 variants
208558	Lynparza	olaparib	https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf	Lynparza is a poly (ADP-ribose) polymerase (PARP) inhibitor indicated for the maintenance treatment of adult patients with deleterious or suspected deleterious gBRCAm metastatic pancreatic adenocarcinoma whose disease has not progressed on at least 16 weeks of a first-line platinum-based chemotherapy regimen. Select patients for therapy based on an FDA-approved companion diagnostic for Lynparza.	deleterious or suspected deleterious gBRCAm	TRUE	(suspected) deleterious gBRCA1 variants; (suspected) deleterious gBRCA2 variants
208558	Lynparza	olaparib	https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf	Lynparza is a poly (ADP-ribose) polymerase (PARP) inhibitor indicated for the treatment of adult patients with deleterious or suspected deleterious germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC) who have progressed following prior treatment with enzalutamide or abiraterone. Select patients for therapy based on an FDA-approved companion diagnostic for Lynparza.	deleterious or suspected deleterious germline or somatic homologous recombination repair (HRR) gene-mutated	TRUE	HRR gene variants
208558	Lynparza	olaparib	https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf	Lynparza is a poly (ADP-ribose) polymerase (PARP) inhibitor indicated in combination with abiraterone and prednisone or prednisolone for the treatment of adult patients with deleterious or suspected deleterious BRCA-mutated (BRCAm) metastatic castration-resistant prostate cancer (mCRPC). Select patients for therapy based on an FDA-approved companion diagnostic for Lynparza.	deleterious or suspected deleterious BRCA-mutated	TRUE	(suspected) deleterious gBRCA1 variants; (suspected) deleterious gBRCA2 variants
215814	Rezlidhia	olutasidenib	https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215814s000lbl.pdf	REZLIDHIA is an isocitrate dehydrogenase-1 (IDH1) inhibitor indicated for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with a susceptible IDH1 mutation as detected by an FDA-approved test.	susceptible IDH1 mutation	TRUE	susceptible IDH1 variants
208065	Tagrisso	osimertinib	https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/208065s033lbl.pdf	"TAGRISSO is a kinase inhibitor indicated for adjuvant therapy after tumor resection in adult patients with non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 L858R mutations, as detected by an FDA-approved test."	EGFR exon 19 deletions or exon 21 L858R mutations	TRUE	EGFR exon 19 deletion variants
208065	Tagrisso	osimertinib	https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/208065s033lbl.pdf	"TAGRISSO is a kinase inhibitor indicated for the first-line treatment of adult patients with metastatic NSCLC whose tumors have EGFR exon 19 deletions or exon 21 L858R mutations, as detected by an FDA-approved test."	EGFR exon 19 deletions or exon 21 L858R mutations	TRUE	EGFR exon 19 deletion variants
208065	Tagrisso	osimertinib	https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/208065s033lbl.pdf	"TAGRISSO is a kinase inhibitor indicated in combination with pemetrexed and platinum-based chemotherapy, the first-line treatment of adult patients with locally advanced or metastatic NSCLC whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 L858R mutations, as detected by an FDA-approved test."	EGFR exon 19 deletions or exon 21 L858R mutations	TRUE	EGFR exon 19 deletion variants
208065	Tagrisso	osimertinib	https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/208065s033lbl.pdf	"TAGRISSO is a kinase inhibitor indicated for the treatment of adult patients with metastatic EGFR T790M mutation-positive NSCLC, as detected by an FDA-approved test, whose disease has progressed on or after EGFR TKI therapy."	EGFR T790M	FALSE	
207103	Ibrance	palbociclib	https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/207103s017s018lbl.pdf	"IBRANCE is a kinase inhibitor indicated for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer in combination with an aromatase inhibitor as initial endocrine-based therapy."	"HR+, HER2-negative"	FALSE	
207103	Ibrance	palbociclib	https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/207103s017s018lbl.pdf	"IBRANCE is a kinase inhibitor indicated for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer in combination with fulvestrant in patients with disease progression following endocrine therapy."	"HR+, HER2-negative"	FALSE	
125147	Vectibix	panitumumab	https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/125147s210lbl.pdf	Vectibix is an epidermal growth factor receptor (EGFR) antagonist indicated for the treatment of wild-type RAS (defined as wild-type in both KRAS and NRAS as determined by an FDA-approved test for this use) metastatic colorectal cancer (mCRC) in combination with FOLFOX for first-line treatment. Limitation of Use: Vectibix is not indicated for the treatment of patients with RAS-mutant mCRC or for whom RAS mutation status is unknown.	wild-type RAS (defined as wild-type in both KRAS and NRAS as determined by an FDA-approved test for this use)	FALSE	
125147	Vectibix	panitumumab	https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/125147s210lbl.pdf	"Vectibix is an epidermal growth factor receptor (EGFR) antagonist indicated for the treatment of wild-type RAS (defined as wild-type in both KRAS and NRAS as determined by an FDA-approved test for this use) metastatic colorectal cancer (mCRC) as monotherapy following disease progression after prior treatment with fluoropyrimidine, oxaliplatin, and irinotecan-containing chemotherapy. Limitation of Use: Vectibix is not indicated for the treatment of patients with RAS-mutant mCRC or for whom RAS mutation status is unknown."	wild-type RAS (defined as wild-type in both KRAS and NRAS as determined by an FDA-approved test for this use)	FALSE	
125514	Keytruda	pembrolizumab	https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/125514s174lbl.pdf	"KEYTRUDA is a programmed death receptor-1 (PD-1)-blocking antibody indicated in combination with pemetrexed and platinum chemotherapy, as first-line treatment of patients with metastatic nonsquamous NSCLC, with no EGFR or ALK genomic tumor aberrations."	no EGFR or ALK genomic tumor aberrations	FALSE	
125514	Keytruda	pembrolizumab	https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/125514s174lbl.pdf	"KEYTRUDA is a programmed death receptor-1 (PD-1)-blocking antibody indicated as a single agent for the first-line treatment of patients with NSCLC expressing PD-L1 [Tumor Proportion Score (TPS) >=1%] as determined by an FDA-approved test, with no EGFR or ALK genomic tumor aberrations, and is: Stage III where patients are not candidates for surgical resection or definitive chemoradiation, or metastatic."	"no EGFR or ALK genomic tumor aberrations, and PD-L1 [Tumor Proportion Score (TPS) >= 1%"	FALSE	
125514	Keytruda	pembrolizumab	https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/125514s174lbl.pdf	"KEYTRUDA is a programmed death receptor-1 (PD-1)-blocking antibody indicated as a single agent for the treatment of patients with metastatic NSCLC whose tumors express PD-L1 (TPS >=1%) as determined by an FDA-approved test, with disease progression on or after platinum containing chemotherapy. Patients with EGFR or ALK genomic tumor aberrations should have disease progression on FDA-approved therapy for these aberrations prior to receiving KEYTRUDA."	PD-L1 [Tumor Proportion Score (TPS) >= 1%	FALSE	
125514	Keytruda	pembrolizumab	https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/125514s174lbl.pdf	"KEYTRUDA is a programmed death receptor-1 (PD-1)-blocking antibody indicated as a single agent for the first-line treatment of patients with metastatic or with unresectable, recurrent HNSCC whose tumors express PD-L1 [Combined Positive Score (CPS) >=1] as determined by an FDA-approved test."	PD-L1 [Combined Positive Score (CPS)] >= 1%	FALSE	
125514	Keytruda	pembrolizumab	https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/125514s174lbl.pdf	"KEYTRUDA is a programmed death receptor-1 (PD-1)-blocking antibody indicated for the treatment of adult and pediatric patients with unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) solid tumors, as determined by an FDA approved test, that have progressed following prior treatment and who have no satisfactory alternative treatment options."	MSI-H or dMMR	FALSE	
125514	Keytruda	pembrolizumab	https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/125514s174lbl.pdf	KEYTRUDA is a programmed death receptor-1 (PD-1)-blocking antibody indicated for the treatment of patients with unresectable or metastatic MSI-H or dMMR colorectal cancer (CRC) as determined by an FDA-approved test.	MSI-H or dMMR	FALSE	
125514	Keytruda	pembrolizumab	https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/125514s174lbl.pdf	"KEYTRUDA is a programmed death receptor-1 (PD-1)-blocking antibody indicated in combination with trastuzumab, fluoropyrimidine- and platinum-containing chemotherapy, for the first-line treatment of adults with locally advanced unresectable or metastatic HER2-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma whose tumors express PD-L1 (CPS >=1) as determined by an FDA-approved test."	HER2-positive... whose tumors express PD-L1 (CPS >= 1)	FALSE	
125514	Keytruda	pembrolizumab	https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/125514s174lbl.pdf	"KEYTRUDA is a programmed death receptor-1 (PD-1)-blocking antibody indicated in combination with fluoropyrimidine- and platinum-containing chemotherapy, for the first-line treatment of adults with locally advanced unresectable or metastatic HER2-negative gastric or gastroesophageal junction (GEJ) adenocarcinoma."	HER2-negative	FALSE	
125514	Keytruda	pembrolizumab	https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/125514s174lbl.pdf	KEYTRUDA is a programmed death receptor-1 (PD-1)-blocking antibody indicated for the treatment of patients with locally advanced or metastatic esophageal or gastroesophageal junction (GEJ) (tumors with epicenter 1 to 5 centimeters above the GEJ) carcinoma that is not amenable to surgical resection or definitive chemoradiation as a single agent after one or more prior lines of systemic therapy for patients with tumors of squamous cell histology that express PD-L1 (CPS >=10) as determined by an FDA-approved test.	PD-L1 (CPS >= 10)	FALSE	
125514	Keytruda	pembrolizumab	https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/125514s174lbl.pdf	"KEYTRUDA is a programmed death receptor-1 (PD-1)-blocking antibody indicated in combination with chemotherapy, with or without bevacizumab, for the treatment of patients with persistent, recurrent, or metastatic cervical cancer whose tumors express PD-L1 (CPS >=1) as determined by an FDA-approved test."	PD-L1 (CPS >= 1)	FALSE	
125514	Keytruda	pembrolizumab	https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/125514s174lbl.pdf	KEYTRUDA is a programmed death receptor-1 (PD-1)-blocking antibody indicated as a single agent for the treatment of patients with recurrent or metastatic cervical cancer with disease progression on or after chemotherapy whose tumors express PD-L1 (CPS >=1) as determined by an FDA-approved test.	PD-L1 (CPS >= 1)	FALSE	
125514	Keytruda	pembrolizumab	https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/125514s174lbl.pdf	"KEYTRUDA is a programmed death receptor-1 (PD-1)-blocking antibody indicated in combination with lenvatinib, for the treatment of patients with advanced endometrial carcinoma that is mismatch repair proficient (pMMR) as determined by an FDA-approved test or not MSI-H, who have disease progression following prior systemic therapy in any setting and are not candidates for curative surgery or radiation."	pMMR or not MSI-H	FALSE	
125514	Keytruda	pembrolizumab	https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/125514s174lbl.pdf	"KEYTRUDA is a programmed death receptor-1 (PD-1)-blocking antibody indicated as a single agent, for the treatment of patients with advanced endometrial carcinoma that is MSI-H or dMMR, as determined by an FDA-approved test, who have disease progression following prior systemic therapy in any setting and are not candidates for curative surgery or radiation."	MSI-H or dMMR	FALSE	
125514	Keytruda	pembrolizumab	https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/125514s174lbl.pdf	"KEYTRUDA is a programmed death receptor-1 (PD-1)-blocking antibody indicated for the treatment of adult and pediatric patients with unresectable or metastatic tumor mutational burden-high (TMB-H) [>=10 mutations/megabase (mut/Mb)] solid tumors, as determined by an FDA-approved test, that have progressed following prior treatment and who have no satisfactory alternative treatment options. The safety and effectiveness of KEYTRUDA in pediatric patients with TMB-H central nervous system cancers have not been established. This indication is approved under accelerated approval based on tumor response rate and durability of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trials."	TMB-H [>= 10 mutations / megabase]	FALSE	
125514	Keytruda	pembrolizumab	https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/125514s174lbl.pdf	"KEYTRUDA is a programmed death receptor-1 (PD-1)-blocking antibody indicated for the treatment of patients with high-risk early-stage TNBC in combination with chemotherapy as neoadjuvant treatment, and then continued as a single agent as adjuvant treatment after surgery."	triple-negative	FALSE	
125514	Keytruda	pembrolizumab	https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/125514s174lbl.pdf	"KEYTRUDA is a programmed death receptor-1 (PD-1)-blocking antibody indicated in combination with chemotherapy, for the treatment of patients with locally recurrent unresectable or metastatic TNBC whose tumors express PD-L1 (CPS >=10) as determined by an FDA approved test."	"triple-negative, PD-L1 (CPS >= 10)"	FALSE	
213736	Pemazyre	pemigatinib	https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/213736s002lbl.pdf	"PEMAZYRE is a kinase inhibitor indicated for the treatment of adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (FGFR2) fusion or other rearrangement as detected by an FDA-approved test. This indication is approved under accelerated approval based on overall response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s)."	FGFR2 fusion or other rearrangement	TRUE	FGFR2::v; FGFR2 rearrangements
213736	Pemazyre	pemigatinib	https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/213736s002lbl.pdf	PEMAZYRE is a kinase inhibitor indicated for the treatment of adults with relapsed or refractory myeloid/lymphoid neoplasms (MLNs) with FGFR1 rearrangement.	FGFR1 rearrangement	TRUE	FGFR1 rearrangement
125409	Perjeta	pertuzumab	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125409s124lbl.pdf	PERJETA is a HER2/neu receptor antagonist indicated for use in combination with trastuzumab and docetaxel for treatment of patients with HER2-positive metastatic breast cancer (MBC) who have not received prior anti-HER2 therapy or chemotherapy for metastatic disease.	HER2-positive	FALSE	
125409	Perjeta	pertuzumab	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125409s124lbl.pdf	"PERJETA is a HER2/neu receptor antagonist indicated for use in combination with trastuzumab and chemotherapy as neoadjuvant treatment of patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer (either greater than 2 cm in diameter or node positive) as part of a complete treatment regimen for early breast cancer."	HER2-positive	FALSE	
125409	Perjeta	pertuzumab	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125409s124lbl.pdf	PERJETA is a HER2/neu receptor antagonist indicated for use in combination with trastuzumab and chemotherapy as adjuvant treatment of patients with HER2-positive early breast cancer at high risk of recurrence.	HER2-positive	FALSE	
761170	Phesgo	pertuzumab and trastuzumab	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761170s000lbl.pdf	"PHESGO is a combination of pertuzumab and trastuzumab, HER2/neu receptor antagonists, and hyaluronidase, an endoglycosidase, indicated for use in combination with chemotherapy as neoadjuvant treatment of patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer (either greater than 2 cm in diameter or node positive) as part of a complete treatment regimen for early breast cancer."	HER2-positive	FALSE	
761170	Phesgo	pertuzumab and trastuzumab	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761170s000lbl.pdf	"PHESGO is a combination of pertuzumab and trastuzumab, HER2/neu receptor antagonists, and hyaluronidase, an endoglycosidase, indicated for use in combination with chemotherapy as adjuvant treatment of patients with HER2-positive early breast cancer at high risk of recurrence."	HER2-positive	FALSE	
761170	Phesgo	pertuzumab and trastuzumab	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761170s000lbl.pdf	"PHESGO is a combination of pertuzumab and trastuzumab, HER2/neu receptor antagonists, and hyaluronidase, an endoglycosidase, indicated for use in combination with docetaxel for treatment of patients with HER2 positive metastatic breast cancer (MBC) who have not received prior anti-HER2 therapy or chemotherapy for metastatic disease."	HER2-positive	FALSE	
203469	Iclusig	ponatinib	https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/203469s037lbl.pdf	"ICLUSIG is a kinase inhibitor indicated for the treatment of adult patients with newly diagnosed Ph+ ALL, in combination with chemotherapy. This indication is approved under accelerated approval based on minimal residual disease (MRD)-negative complete remission (CR) at the end of induction. Continued approval for this indication may be contingent upon verification of clinical benefit in a confirmatory trial(s)."	Ph+	FALSE	
203469	Iclusig	ponatinib	https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/203469s037lbl.pdf	ICLUSIG is a kinase inhibitor indicated for the treatment of adult patients with as monotherapy in Ph+ ALL for whom no other kinase inhibitors are indicated or T315I-positive Ph+ ALL.	Ph+ and T315I	FALSE	
203469	Iclusig	ponatinib	https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/203469s037lbl.pdf	"ICLUSIG is a kinase inhibitor indicated for the treatment of adult patients with T315I-positive CML (chronic phase, accelerated phase, or blast phase). Limitations of Use: ICLUSIG is not indicated and is not recommended for the treatment of patients with newly diagnosed CP-CML."	T315I-positive	FALSE	
213721	Gavreto	pralsetinib	https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/213721s015lbl.pdf	GAVRETO is a kinase inhibitor indicated for treatment of adult patients with metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer as detected by an FDA approved test (NSCLC).	RET fusion-positive	TRUE	v::RET
213721	Gavreto	pralsetinib	https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/213721s015lbl.pdf	GAVRETO is a kinase inhibitor indicated for treatment of adult and pediatric patients 12 years of age and older with advanced or metastatic RET fusion-positive thyroid cancer who require systemic therapy and who are radioactive iodine-refractory (if radioactive iodine is appropriate). This indication is approved under accelerated approval based on overall response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trial(s).	RET fusion-positive	TRUE	v::RET
125477	Cyramza	ramucirumab	https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/125477s042lbl.pdf	"CYRAMZA is a human vascular endothelial growth factor receptor 2 (VEGFR2) antagonist indicated in combination with erlotinib, for first-line treatment of metastatic non-small cell lung cancer with epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) mutations."	EGFR exon 19 deletions or exon 21 (L858R)	TRUE	EGFR exon 19 deletion variants
218213	Augtyro	repotrectinib	https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/218213s001lbl.pdf	AUGTYRO is a kinase inhibitor indicated for the treatment of adult patients with locally advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC).	ROS1-positive	TRUE	v::ROS1
218213	Augtyro	repotrectinib	https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/218213s001lbl.pdf	"AUGTYRO is a kinase inhibitor indicated for the treatment of adult and pedatric patients 12 years of age and older with solid tumors that (i) have a neutrophic tyrosine receptor kinase (NTRK) gene fusion and (ii) are locally advanced or metastatic or where surgical resection is likely to result in severe morbility, and (iii) have progressed following treatment or have no satisfactory alternative therapy. This indication is approved under accelerated approval based on overall response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials."	NTRK gene fusions	TRUE	v::NTRK1; v::NTRK2; v::NTRK3
209092	Kisqali	ribociclib	https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/209092Orig1s018lbl.pdf	"KISQALI is a kinase inhibitor indicated for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer in combination with an aromatase inhibitor as initial endocrine-based therapy."	"HR-positive, HER2-negative"	FALSE	
209092	Kisqali	ribociclib	https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/209092Orig1s018lbl.pdf	"KISQALI is a kinase inhibitor indicated for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer in combination with fulvestrant as initial endocrine-based therapy or following disease progression on endocrine therapy."	"HR-positive, HER2-negative"	FALSE	
103705	Rituxan	rituximab	https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/103705s5467lbl.pdf	"RITUXAN is a CD20-directed cytolytic antibody indicated for the treatment of adult patients with relapsed or refractory, low grade or follicular, CD20-positive B- cell NHL as a single agent."	CD20-positive	FALSE	
103705	Rituxan	rituximab	https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/103705s5467lbl.pdf	"RITUXAN is a CD20-directed cytolytic antibody indicated for the treatment of adult patients with previously untreated follicular, CD20-positive, B-cell Non-Hodgkin's Lymphoma (NHL) in combination with first line chemotherapy and, in patients achieving a complete or partial response to a rituximab product in combination with chemotherapy, as single-agent maintenance therapy."	CD20-positive	FALSE	
103705	Rituxan	rituximab	https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/103705s5467lbl.pdf	"RITUXAN is a CD20-directed cytolytic antibody indicated for the treatment of adult patients with Non-Hodgkin's Lymphoma (NHL) non-progressing (including stable disease), low-grade, CD20 positive, B-cell NHL as a single agent after first-line cyclophosphamide, vincristine, and prednisone (CVP) chemotherapy."	CD20 positive	FALSE	
103705	Rituxan	rituximab	https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/103705s5467lbl.pdf	"RITUXAN is a CD20-directed cytolytic antibody indicated for the treatment of adult patients with Non-Hodgkin's Lymphoma (NHL) previously untreated diffuse large B-cell, CD20-positive NHL in combination with (cyclophosphamide, doxorubicin, vincristine, and prednisone) (CHOP) or other anthracycline-based chemotherapy regimens."	CD20-positive	FALSE	
103705	Rituxan	rituximab	https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/103705s5467lbl.pdf	"RITUXAN is a CD20-directed cytolytic antibody indicated for the treatment of pediatric patients aged 6 months and older with previously untreated, advanced stage, CD20-positive, diffuse large B-cell lymphoma (DLBCL), Burkitt lymphoma (BL), Burkitt-like lymphoma (BLL) or mature B-cell acute leukemia (B-AL) in combination with chemotherapy."	CD20-positive	FALSE	
103705	Rituxan	rituximab	https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/103705s5467lbl.pdf	RITUXAN is a CD20-directed cytolytic antibody indicated for the treatment of adult patients with previously untreated and previously treated CD20-positive Chronic Lymphocytic Leukemia (CLL).	CD20-positive	FALSE	
209115	Rubraca	rucaparib	https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/209115s013lbl.pdf	"RUBRACA is a poly (ADP-ribose) polymerase (PARP) inhibitor indicated for the maintenance treatment of adult patients with a deleterious BRCA mutation (germline and/or somatic)- associated recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy."	deleterious BRCA mutation (germline and/or somatic)	TRUE	deleterious BRCA1 variants; deleterious BRCA2 variants
209115	Rubraca	rucaparib	https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/209115s013lbl.pdf	RUBRACA is a poly (ADP-ribose) polymerase (PARP) inhibitor indicated for the treatment of adult patients with a deleterious BRCA mutation (germline and/or somatic)-associated metastatic castration-resistant prostate cancer (mCRPC) who have been treated with androgen receptor-directed therapy and a taxane-based chemotherapy. Select patients for therapy based on an FDA-approved companion diagnostic for RUBRACA. This indication is approved under accelerated approval based on objective response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.	deleterious BRCA mutation (germline and/or somatic)	TRUE	deleterious BRCA1 variants; deleterious BRCA2 variants
761115	Trodelvy	sacituzumab govitecan	https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/761115s035lbl.pdf	"TRODELVY is a Trop-2-directed antibody and topoisomerase inhibitor conjugate indicated for the treatment of adult patients with unresectable locally advanced or metastatic triple-negative breast cancer (mTNBC) who have received two or more prior systemic therapies, at least one of them for metastatic disease."	triple-negative breast cancer	FALSE	
761115	Trodelvy	sacituzumab govitecan	https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/761115s035lbl.pdf	"TRODELVY is a Trop-2-directed antibody and topoisomerase inhibitor conjugate indicated for the treatment of adult patients with unresectable locally advanced or metastatic hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative (IHC 0, IHC 1+ or IHC 2+/ISH-) breast cancer who have received endocrine-based therapy and at least two additional systemic therapies in the metastatic setting."	"HR-positive, HER2-negative (HC 0, IHC 1+, or IHC 2+/ISH-)"	FALSE	
213246	Retevmo	selpercatinib	https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/213246s011s013lbl.pdf	"RETEVMO is a kinase inhibitor indicated for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with a rearranged during transfection (RET) gene fusion, as detected by an FDA-approved test."	RET fusion	TRUE	v::RET
213246	Retevmo	selpercatinib	https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/213246s011s013lbl.pdf	"RETEVMO is a kinase inhibitor indicated for the treatment of adult and pediatric patients 2 years of age and older with advanced or metastatic medullary thyroid cancer (MTC) with a RET mutation, as detected by an FDA-approved test, who require systemic therapy."	RET mutation	TRUE	RET variants
213246	Retevmo	selpercatinib	https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/213246s011s013lbl.pdf	"RETEVMO is a kinase inhibitor indicated for the treatment of adult and pediatric patients 2 years of age and older with advanced or metastatic thyroid cancer with a RET gene fusion, as detected by an FDA-approved test, who require systemic therapy and who are radioactive iodine-refractory (if radioactive iodine is appropriate)."	RET gene fusion	TRUE	v::RET
213246	Retevmo	selpercatinib	https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/213246s011s013lbl.pdf	"RETEVMO is a kinase inhibitor indicated for the treatment of adult and pediatric patients 2 years of age and older with locally advanced or metastatic solid tumors with a RET gene fusion, as detected by an FDA-approved test, that have progressed on or following prior systemic treatment or who have no satisfactory alternative treatment options. This indication is approved under accelerated approval based on overall response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trial(s)."	RET gene fusion	TRUE	v::RET
214665	Lumakras	sotorasib	https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/214665s004lbl.pdf	"LUMAKRAS is an inhibitor of the RAS GTPase family indicated for the treatment of adult patients with KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC), as determined by an FDA-approved test, who have received at least one prior systemic therapy. This indication is approved under accelerated approval based on overall response rate (ORR) and duration of response (DOR). Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s)."	KRAS G12C	FALSE	
211651	Talzenna	talazoparib	https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/211651s012lbl.pdf	TALZENNA is a poly (ADP-ribose) polymerase (PARP) inhibitor indicated as a single agent for the treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm) HER2-negative locally advanced or metastatic breast cancer. Select patients for therapy based on an FDA-approved companion diagnostic for TALZENNA.	"deleterious or suspected deleterious germline BRCA-mutated (gBRCAm), HER2-negative"	TRUE	(suspected) deleterious gBRCA1 variants; (suspected) deleterious gBRCA2 variants
211651	Talzenna	talazoparib	https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/211651s012lbl.pdf	TALZENNA is a poly (ADP-ribose) polymerase (PARP) inhibitor indicated in combination with enzalutamide for the treatment of adult patients with HRR gene-mutated metastatic castration-resistant prostate cancer (mCRPC).	HRR gene-mutated	TRUE	HRR gene variants
211723	Tazverik	tazemetostat	https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211723s004lbl.pdf	TAZVERIK is a methyltransferase inhibitor indicated for the treatment of adult patients with relapsed or refractory follicular lymphoma whose tumors are positive for an EZH2 mutation as detected by an FDA-approved test and who have received at least 2 prior systemic therapies. These indications are approved under accelerated approval based on overall response rate and duration of response. Continued approval for these indications may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).	EZH2 mutation positive	TRUE	EZH2 variants
214096	Tepmetko	tepotinib	https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/214096s003lbl.pdf	TEPMETKO is a kinase inhibitor indicated for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) harboring mesenchymal-epithelial transition (MET) exon 14 skipping alterations.	MET exon 14 skipping alterations	TRUE	MET exon 14 skipping variants
217513	Mekinist	trametinib	https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/217513s003lbl.pdf	MEKINIST is a kinase inhibitor indicated as a single agent for the treatment of BRAF-inhibitor treatment-naive patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutations as detected by an FDA-approved test.	BRAF V600E or V600K	FALSE	
217513	Mekinist	trametinib	https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/217513s003lbl.pdf	"MEKINIST is indicated, in combination with dabrafenib, for the treatment of patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutations as detected by an FDA-approved test."	BRAF V600E or V600K	FALSE	
217513	Mekinist	trametinib	https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/217513s003lbl.pdf	"MEKINIST is indicated, in combination with dabrafenib, for the adjuvant treatment of patients with melanoma with BRAF V600E or V600K mutations, as detected by an FDA-approved test, and involvement of lymph node(s), following complete resection."	BRAF V600E or V600K	FALSE	
217513	Mekinist	trametinib	https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/217513s003lbl.pdf	"MEKINIST is indicated, in combination with dabrafenib, for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) with BRAF V600E mutation as detected by an FDA-approved test."	BRAF V600E	FALSE	
217513	Mekinist	trametinib	https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/217513s003lbl.pdf	"MEKINIST is indicated, in combination with dabrafenib, for the treatment of patients with locally advanced or metastatic anaplastic thyroid cancer (ATC) with BRAF V600E mutation and with no satisfactory locoregional treatment options."	BRAF V600E	FALSE	
217513	Mekinist	trametinib	https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/217513s003lbl.pdf	"MEKINIST is indicated, in combination with dabrafenib, for the treatment of adult and pediatric patients 1 year of age and older with unresectable or metastatic solid tumors with BRAF V600E mutation who have progressed following prior treatment and have no satisfactory alternative treatment options. This indication is approved under accelerated approval based on overall response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s). Limitations of Use: MEKINIST is not indicated for treatment of patients with colorectal cancer because of known intrinsic resistance to BRAF inhibition."	BRAF V600E	FALSE	
217513	Mekinist	trametinib	https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/217513s003lbl.pdf	"MEKINIST is indicated, in combination with dabrafenib, for the treatment of pediatric patients 1 year of age and older with low-grade glioma (LGG) with a BRAF V600E mutation who require systemic therapy."	BRAF V600E	FALSE	
103792	Herceptin	trastuzumab	https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/103792s5354lbl.pdf	Herceptin is a HER2/neu receptor antagonist indicated for the treatment of HER2 -overexpressing breast cancer. Select patients for therapy based on an FDA-approved companion diagnostic for Herceptin.	HER2-overexpressing	FALSE	
103792	Herceptin	trastuzumab	https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/103792s5354lbl.pdf	Herceptin is a HER2/neu receptor antagonist indicated for the treatment of HER2-overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma. Select patients for therapy based on an FDA-approved companion diagnostic for Herceptin.	HER2-overexpressing	FALSE	
761139	Enhertu	trastuzumab deruxtecan	https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761139s028lbl.pdf	"ENHERTU is a HER2-directed antibody and topoisomerase inhibitor conjugate indicated for the treatment of adult patients with unresectable or metastatic HER2-positive (IHC 3+ or ISH positive) breast cancer who have received a prior anti-HER2-based regimen either (i) in the metastatic setting, or (ii) in the neoadjuvant or adjuvant setting and have developed disease recurrence during or within six months of completing therapy."	HER2-positive (IHC 3+ or ISH positive)	FALSE	
761139	Enhertu	trastuzumab deruxtecan	https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761139s028lbl.pdf	"ENHERTU is a HER2-directed antibody and topoisomerase inhibitor conjugate indicated for the treatment of adult patients with unresectable or metastatic HER2-low (IHC 1+ or IHC 2+/ISH-) breast cancer, as determined by an FDA-approved test, who have received a prior chemotherapy in the metastatic setting or developed disease recurrence during or within 6 months of completing adjuvant chemotherapy."	HER2-low (IHC 1+ or IHC2+/ISH-)	FALSE	
761139	Enhertu	trastuzumab deruxtecan	https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761139s028lbl.pdf	"ENHERTU is a HER2-directed antibody and topoisomerase inhibitor conjugate indicated for the treatment of adult patients with unresectable or metastatic non-small cell lung cancer (NSCLC) whose tumors have activating HER2 (ERBB2) mutations, as detected by an FDA-approved test, and who have received a prior systemic therapy. These indications are approved under accelerated approval based on objective response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial."	HER2 (ERBB2) mutations	TRUE	HER2 (ERBB2) variants
761139	Enhertu	trastuzumab deruxtecan	https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761139s028lbl.pdf	ENHERTU is a HER2-directed antibody and topoisomerase inhibitor conjugate indicated for the treatment of adult patients with locally advanced or metastatic HER2-positive (IHC 3+ or IHC 2+/ISH positive) gastric or gastroesophageal junction adenocarcinoma who have received a prior trastuzumab-based regimen.	HER2-positive (IHC 3+ or IHC 2+/ISH positive)	FALSE	
761139	Enhertu	trastuzumab deruxtecan	https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761139s028lbl.pdf	ENHERTU is a HER2-directed antibody and topoisomerase inhibitor conjugate indicated for the treatment of adult patients with unresectable or metastatic HER2-positive (IHC 3+) solid tumors who have received prior systemic treatment and have no satisfactory alternative treatment options. These indications are approved under accelerated approval based on objective response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial.	HER2-positive (IHC 3+)	FALSE	
761270	Imjudo	tremelimumab-actl	https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761270s000lbl.pdf	IMJUDO is a cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) blocking antibody indicated in combination with durvalumab and platinum-based chemotherapy for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) with no sensitizing epidermal growth factor receptor (EGFR) mutation or anaplastic lymphoma kinase (ALK) genomic tumor aberrations.	no sensitizing EGFR mutation or ALK genomic tumor aberrations	FALSE	
213411	Tukysa	tucatinib	https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/213411s004lbl.pdf	"TUKYSA is a kinase inhibitor indicated in combination with trastuzumab and capecitabine for treatment of adult patients with advanced unresectable or metastatic HER2-positive breast cancer, including patients with brain metastases, who have received one or more prior anti-HER2-based regimens in the metastatic setting."	HER2-positive	FALSE	
213411	Tukysa	tucatinib	https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/213411s004lbl.pdf	"TUKYSA is a kinase inhibitor indicated in combination with trastuzumab for the treatment of adult patients with RAS wild-type HER2-positive unresectable or metastatic colorectal cancer that has progressed following treatment with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy. This indication is approved under accelerated approval based on tumor response rate and durability of response [see Clinical Studies (14.2)]. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials."	"RAS wild-type, HER2-positive"	FALSE	
202429	Zelboraf	vemurafenib	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202429s019lbl.pdf	ZELBORAF is a kinase inhibitor indicated for the treatment of patients with unresectable or metastatic melanoma with BRAF V600E mutation as detected by an FDA-approved test.	BRAF V600E	FALSE	
202429	Zelboraf	vemurafenib	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202429s019lbl.pdf	ZELBORAF is indicated for the treatment of patients with Erdheim-Chester Disease with BRAF V600 mutation.	BRAF V600	TRUE	BRAF V600
208065	Tagrisso	osimertinib	https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/208065s033lbl.pdf	"TAGRISSO is a kinase inhibitor indicated for the treatment of adult patients with locally advanced, unresectable (stage III) NSCLC whose disease has not progressed during or following concurrent or sequential platinum-based chemoradiation therapy and whose tumors have EGFR exon 19 deletions or exon 21 L858R mutations, as detected by an FDA-approved test."	EGFR exon 19 deletions or exon 21 L858R	TRUE	EGFR exon 19 deletion variants
761210	Rybrevant	amivantamab-vmjw	https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761210s004lbl.pdf	"RYBREVANT is a bispecific EGF receptor-directed and MET receptor-directed antibody indicated in combination with lazertinib for the first-line treatment of adult patients with locally advanced or metastatic NSCLC with EGFR exon 19 deletions or exon 21 L858R substitution mutations, as detected by an FDA-approved test."	EGFR exon 19 deletions or exon 21 L858R	TRUE	EGFR exon 19 deletion variants
219008	Lazcluze	lazertinib	https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/219008s000lbledt.pdf	"LAZCLUZE is a kinase inhibitor indicated in combination with amivantamab for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 L858R substitution mutations, as detected by an FDA-approved test."	EGFR exon 19 deletions or exon 21 L858R	TRUE	EGFR exon 19 deletion variants
761210	Rybrevant	amivantamab-vmjw	https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761210s004lbl.pdf	"RYBREVANT is a bispecific EGF receptor-directed and MET receptor-directed antibody indicated in combination with carboplatin and pemetrexed for the treatment of adult patients with locally advanced or metastatic NSCLC with EGFR exon 19 deletions or exon 21 L858R substitution mutations, whose disease has progressed on or after treatment with an EGFR tyrosine kinase inhibitor."	EGFR exon 19 deletions or exon 21 L858R	TRUE	EGFR exon 19 deletion variants
761310	Elahere	mirvetuximab soravtansine-gynx	https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761310Origs005lbl.pdf	"ELAHERE is a folate receptor alpha (FR)-directed antibody and microtubule inhibitor conjugate indicated for the treatment of adult patients with FR-alpha positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer, who have received one to three prior systemic treatment regimens. Select patients for therapy based on an FDA-approved test."	folate receptor-alpha tumor expression	FALSE	
217700	Ojemda	tovorafenib	https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/217700s000lbl.pdf	"OJEMDA is a kinase inhibitor indicated for the treatment of patients 6 months of age and older with relapsed or refractory pediatric low-grade glioma (LGG) harboring a BRAF fusion or rearrangement, or BRAF V600 mutation."	"BRAF fusion or rearrangement, or BRAF V600 mutation"	TRUE	BRAF V600; BRAF rearrangements; v::BRAF
761069	Imfinzi	durvalumab	https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761069s043lbledt.pdf	"IMFINZI is a programmed death-ligand 1 (PD-L1) blocking antibody indicated in combination with platinum-containing chemotherapy as neoadjuvant treatment, followed by IMFINZI continued as a single agent as adjuvant treatment after surgery, for the treatment of adult patients with resectable (tumors  4 cm and/or node positive) non-small cell lung cancer (NSCLC) and no known epidermal growth factor receptor (EGFR) mutations or anaplastic lymphoma kinase (ALK) rearrangements."	no known epidermal growth factor receptor (EGFR) mutations or anaplastic lymphoma kinase (ALK) rearrangements.	FALSE	
216340	Krazati	adagrasib	https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/216340Orig1s000Corrected_lbl.pdf	"KRAZATI is an inhibitor of the RAS GTPase family indicated in combination with cetuximab for the treatment of adult patients with KRAS G12C-mutated locally advanced or metastatic CRC, as determined by an FDA-approved test, who have received prior treatment with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy. These indications are approved under accelerated approval based on objective response rate (ORR) and duration of response (DOR). Continued approval for these indications may be contingent upon verification and description of a clinical benefit in confirmatory trials."	KRAS G12C	FALSE	
218784	Voranigo	vorasidenib	https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/218784s000lbl.pdf	"VORANIGO is an isocitrate dehydrogenase-1 (IDH1) and isocitrate dehydrogenase-2 (IDH2) inhibitor indicated for the treatment of adult and pediatric patients 12 years and older with Grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation following surgery including biopsy, sub-total resection, or gross total resection."	IDH1 or IDH2 mutations	TRUE	IDH1 variants; IDH2 variants
209092	Kisqali	ribociclib	https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/209092Orig1s018lbl.pdf	"KISQALI is a kinase inhibitor indicated in combination with an aromatase inhibitor for the adjuvant treatment of adults with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative stage II and III early breast cancer at high risk of recurrence."	"hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative"	FALSE	
125554	Opdivo	nivolumab	https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/125554s129lbl.pdf	"OPDIVO is a programmed death receptor-1 (PD-1)-blocking antibody indicated for the treatment of adult patients with metastatic non-small cell lung cancer expressing PD-L1 (>= 1%) as determined by an FDA-approved test, with no EGFR or ALK genomic tumor aberrations, as first-line treatment in combination with ipilimumab."	PD-L1 (>= 1%)	FALSE	
125554	Opdivo	nivolumab	https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/125554s129lbl.pdf	"OPDIVO is a programmed death receptor-1 (PD-1)-blocking antibody indicated for the treatment of adult patients with metastatic or recurrent non-small cell lung cancer with no EGFR or ALK genomic tumor aberrations as first-line treatment, in combination with ipilimumab and 2 cycles of platinum-doublet chemotherapy."	no EGFR or ALK genomic tumor aberrations	FALSE	
125554	Opdivo	nivolumab	https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/125554s129lbl.pdf	"OPDIVO is a programmed death receptor-1 (PD-1)-blocking antibody indicated for the treatment of adult and pediatric (12 years and older) patients with microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) metastatic colorectal cancer that has progressed following treatment with a fluoropyrimidine, oxaliplatin, and irinotecan."	microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR)	FALSE	
219249	Itovebi	inavolisib	https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/219249s000lbl.pdf	"ITOVEBI is a kinase inhibitor indicated in combination with palbociclib and fulvestrant for the treatment of adults with endocrine-resistant, PIK3CA-mutated, hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer, as detected by an FDA-approved test, following recurrence on or after completing adjuvant endocrine therapy."	"PIK3CA-mutated, hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative"	TRUE	PIK3CA variants
761365	Vyloy	zolbetuximab	https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761365s000lbl.pdf	VYLOY is a claudin 18.2-directed cytolytic antibody and is indicated in combination with fluoropyrimidine- and platinum-containing chemotherapy for the first-line treatment of adults with locally advanced unresectable or metastatic human epidermal growth factor receptor 2 (HER2)-negative gastric or gastroesophageal junction adenocarcinoma whose tumors are claudin (CLDN) 18.2 positive as determined by an FDA-approved test.	human epidermal growth factor receptor 2 (HER2)-negative .. claudin (CLDN) 18.2 positive	FALSE	
761416	Ziihera	zanidatamab-hrii	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2024/761416Orig1s000Lbl.pdf	"ZIHERA is a bispecific HER2-directed antibody indicated for the treatment of adults with previously treated, unresectable or metastatic HER2-positive (IHC 3+) biliary tract cancer (BTC), as detected by an FDA-approved test. This indication is approved under accelerated approval based on overall response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s)."	HER2-positive (IHC 3+)	FALSE	
761352	Bizengri	zenocutuzumab-zbco	https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761352s001lbl.pdf	"BIZENGRI is a bispecific HER2- and HER3-directed antibody indicated for the treatment of adults with advanced, unresectable or metastatic non-small cell lung cancer (NSCLC) harboring a neuregulin 1 (NRG1) gene fusion with disease progression on or after prior systemic therapy. This indication is approved under accelerated approval based on overall response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s)."	NGR1 gene fusion	TRUE	v::NRG1
761352	Bizengri	zenocutuzumab-zbco	https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761352s001lbl.pdf	"BIZENGRI is a bispecific HER2- and HER3-directed antibody indicated for the treatment of adults with advanced, unresectable or metastatic pancreatic adenocarcinoma harboring a neuregulin 1 (NRG1) gene fusion with disease progression on or after prior systemic therapy. This indication is approved under accelerated approval based on overall response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s)."	NRG1 gene fusion	TRUE	v::NRG1
218171	Ensacove	ensartinib	https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/218171s000lbl.pdf	ENSACOVE is a kinase inhibitor indicated for the treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive locally advanced or metastatic non-small cell lung cancer (NSCLC) who have not previously received an ALK-inhibitor.	ALK-positive	TRUE	v::ALK
210496	Braftovi	encorafenib	https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/210496s017lbl.pdf	"BRAFTOVI is a kinase inhibitor indicated in combination with cetuximab and mFOLFOX6, for the treatment of patients with metastatic colorectal cancer (mCRC) with a BRAF V600E mutation, as detected by an FDA-approved test. This indication is approved under accelerated approval based on response rate and durability of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s). BRAFTOVI is not indicated for treatment of patients with wild-type BRAF melanoma, wild-type BRAF CRC, or wild-type BRAF NSCLC."	BRAF V600E	FALSE	
215358	Scemblix	asciminib	https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/215358Orig1s008lbl.pdf	SCEMBLIX is a kinase inhibitor indicated for the treatment of adult patients with newly diagnosed philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phase (CP). This indication is approved under accelerated approval based on major molecular response rate. Continued approval for this indication may be contingent upon verification of clinical benefit in a confirmatory trial(s).	philadelphia chromosome-positive	FALSE	
218944	Revuforj	revumenib	https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/218944s000lbl.pdf	REVUFORJ is a menin inhibitor indicated for the treatment of relapsed or refractory acute leukemia with a lysine methyltransferase 2A gene (KMT2A) translocation in adult and pediatric patients 1 year and older.	KMT2A translocation	TRUE	KMT2A translocations
22334	Afinitor	everolimus	"https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/203985s023,022334s051lbl.pdf"	"AFINITOR is a kinase inhibitor indicated for the treatment of adults with renal angiomyolipoma and tuberous sclerosis complex (TSC), not requiring immediate surgery."	TSC1/2	TRUE	TSC1 variants; TSC2 variants
22334	Afinitor	everolimus	"https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/203985s023,022334s051lbl.pdf"	AFINITOR and AFINITOR DISPERZ are kinase inhibitors indicated for the treatment of adult and pediatric patients aged 1 year and older with TSC who have subependymal giant cell astrocytoma (SEGA) that requires therapeutic intervention but cannot be curatively resected.	TSC1/2	TRUE	TSC1 variants; TSC2 variants
125554	Opdivo	nivolumab	https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/125554s129lbl.pdf	OPDIVO is a programmed death receptor-1 (PD-1)-blocking antibody indicated for the treatment of adult and pediatric (12 years and older) patients with unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) colorectal cancer (CRC) in combination with ipilimumab.	microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR)	FALSE	
219713	Ibtrozi	taletrectinib	https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/219713s000lbl.pdf	IBTROZI is a kinase inhibitor indicated for the treatment of adult patients with locally advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC).	ROS1-positive	TRUE	v::ROS1
761384	Emrelis	telisotuzumab vedotin	https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/761384s000lbl.pdf	"EMRELIS is a c-Met-directed antibody and microtubule inhibitor conjugate indicated for the treatment of adult patients with locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) with high c-Met protein overexpression [>=50% of tumor cells with strong (3+) staining], as determined by an FDA-approved test, who have received a prior systemic therapy."	high c-Met protein overexpression [>=50% of tumor cells with strong (3+) staining]	FALSE	
219616	Avmapki Fakzynja co-pack	avutometinib; defactinib	https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/219616s000lbl.pdf	"AVMAPKI FAKZYNJA CO-PACK, a combination of avutometinib and defactinib, each kinase inhibitors, is indicated for the treatment of adult patients with KRAS-mutated recurrent low-grade serous ovarian cancer (LGSOC) who have received prior systemic therapy."	KRAS-mutated	TRUE	KRAS variants